- * In New York Heart Association (NYHA) II-III functional class due to stable symptomatic chronic heart failure (CHF)
- * Left ventricular ejection fraction (LVEF) 40% or lower for patients in NYHA II and 45% or lower in NYHA III
- * Screening haemoglobin (Hb) at least 9.5 g/dL but below or equal to 13.5 g/dL (average of 2 haemoglobin concentrations)
- * Screening ferritin below 100 µg/L, or below 300 µg/L when transferrin saturation (TSAT) is below 20%
Chronic Heart Failure
EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure
NCT00821717 | PHASE 3 | INTERVENTIONAL
This study is designed to assess, relative to placebo, the effects on the evolution of exercise capacity and symptomatic status of the addition of iron treatment with FCM (ferric carboxymaltose) to the basic regimen of ambulatory patients with stable symptomatic chronic CHF (congestive heart failure) and iron deficiency.
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
Research Site
Copenhagen S,Denmark
Research Site
Esbjerg,Denmark
Research Site
Fredericia,Denmark
Research Site
Glostrup,Denmark
Research Site
Hellerup,Denmark
Research Site
Herning,Denmark
Research Site
Hilleroed,Denmark
Research Site
Svendborg,Denmark
Research Site
Boulogne,France
Research Site
Dijon,France
Research Site
Lyon,France
Research Site
Montpellier,France
Research Site
Nantes,France
Research Site
Pontoise,France
Research Site
Rennes,France
Research Site
Saintes,France
Research Site
Strasbourg,France
Research Site
Dueren,Germany
Research Site
Frankfurt,Germany
Research Site
Homburg/Saar,Germany
Research Site
Koeln,Germany
Research Site
Mainz,Germany
Research Site
Würzburg,Germany
Research Site
Afula,Israel
Research Site
Ashkelon,Israel
Research Site
Haifa,Israel
Research Site
Holon,Israel
Research Site
Jerusalem,Israel
Research Site
Kfar-Saba,Israel
Research Site
Rehovot,Israel
Research Site
Tel-Aviv,Israel
Research Site
Tel-Hashomer,Israel
Research Site
Zefat,Israel
Research Site
Amsterdam,Netherlands
Research Site
Den Bosch,Netherlands
Research Site
Eindhoven,Netherlands
Research Site
Heerenveen,Netherlands
Research Site
Leiden,Netherlands
Research Site
Nieuwegein,Netherlands
Research Site
Tilburg,Netherlands
Research Site
Utrecht,Netherlands
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov